Payment overview · 2025
General Payments
$3,000.83
170 reported records · 31 companies
Healthcare provider profile · identity verified
Guy D Roberts, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FARMINGTON, MO · NPI 1528085156
Verified facts
What the public records show
CMS Open Payments records show Guy D Roberts, D.O. received $3,000.83 in general payments during 2025 across 170 reported records.
ABBVIE INC. accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Ingrezza, Jardiance, Linzess, Mounjaro, Otezla, Ozempic, Rexulti, Veozah, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 796 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 796 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $509.05 | 17.0% | 38 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $251.91 | 8.4% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $192.35 | 6.4% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $182.46 | 6.1% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $153.18 | 5.1% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.49 | 4.8% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $137.65 | 4.6% | 8 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $137.31 | 4.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $136.78 | 4.6% | 11 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $113.61 | 3.8% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.09 | 3.7% | 6 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $107.38 | 3.6% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $106.43 | 3.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $102.01 | 3.4% | 5 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $94.20 | 3.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $76.48 | 2.5% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $63.54 | 2.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $62.09 | 2.1% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $47.17 | 1.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.12 | 1.2% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.18 | 1.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $31.60 | 1.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.16 | 1.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.78 | 0.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.24 | 0.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.22 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.71 | 0.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.89 | 0.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.83 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.85 | 0.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.07 | 0.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,912.14 | 168 |
| Education | $88.69 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $314.00 | 16 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $192.35 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $178.20 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $161.05 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $159.70 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $153.95 | 11 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $137.31 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $133.41 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $133.41 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $113.61 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $113.43 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $111.09 | 6 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $107.38 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $103.67 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $102.01 | 5 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $94.20 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $89.30 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $87.19 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.76 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $65.02 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $63.54 | 3 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $59.69 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $47.17 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.90 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $34.18 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $33.98 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $31.60 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.16 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $25.31 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.31 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.76 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.76 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.76 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $13.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.07 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $10.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 796 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 131 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 215 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 72 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 152 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
152 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
315 | 29 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
215 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
796 | 68 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
137 | 29 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
247 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
215 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
146 | 27 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 33 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
796 | 68 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 2177 | 292 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2041 | 325 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1509 | 322 |
| Gabapentin | Gabapentin | 1372 | 194 |
| Amlodipine Besylate | Amlodipine Besylate | 1037 | 186 |
| Pantoprazole Sodium | Pantoprazole Sodium | 994 | 139 |
| Omeprazole | Omeprazole | 935 | 179 |
| Alprazolam | Alprazolam | 900 | 150 |
| Lisinopril | Lisinopril | 882 | 169 |
| Furosemide | Furosemide | 868 | 132 |
| Eliquis | Apixaban | 796 | 68 |
| Metformin Hcl | Metformin Hcl | 706 | 147 |
| Tamsulosin Hcl | Tamsulosin Hcl | 679 | 114 |
| Tramadol Hcl | Tramadol Hcl | 651 | 175 |
| Trazodone Hcl | Trazodone Hcl | 645 | 101 |
| Mirtazapine | Mirtazapine | 641 | 96 |
| Potassium Chloride | Potassium Chloride | 632 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 619 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 557 | 89 |
| Montelukast Sodium | Montelukast Sodium | 554 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 543 | 103 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 490 | 91 |
| Duloxetine Hcl | Duloxetine Hcl | 487 | 73 |
| Celecoxib | Celecoxib | 480 | 76 |
| Sertraline Hcl | Sertraline Hcl | 458 | 74 |
| Donepezil Hcl | Donepezil Hcl | 445 | 57 |
| Losartan Potassium | Losartan Potassium | 438 | 91 |
| Clopidogrel | Clopidogrel Bisulfate | 416 | 65 |
| Carvedilol | Carvedilol | 403 | 70 |
| Famotidine | Famotidine | 389 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 343 | 57 |
| Buspirone Hcl | Buspirone Hcl | 342 | 58 |
| Pregabalin | Pregabalin | 329 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 323 | 114 |
| Myrbetriq | Mirabegron | 315 | 29 |
| Allopurinol | Allopurinol | 310 | 46 |
| Lorazepam | Lorazepam | 309 | 80 |
| Quetiapine Fumarate | Quetiapine Fumarate | 299 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 293 | 47 |
| Diazepam | Diazepam | 285 | 56 |
| Spironolactone | Spironolactone | 283 | 48 |
| Divalproex Sodium | Divalproex Sodium | 280 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 277 | 37 |
| Prednisone | Prednisone | 259 | 137 |
| Meloxicam | Meloxicam | 258 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 258 | 42 |
| Xarelto | Rivaroxaban | 247 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 246 | 42 |
| Baclofen | Baclofen | 245 | 36 |
| Clonazepam | Clonazepam | 240 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 233 | 34 |
| Finasteride | Finasteride | 232 | 37 |
| Memantine Hcl | Memantine Hcl | 232 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 222 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 216 | 56 |
| Jardiance | Empagliflozin | 215 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 215 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 214 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 205 | 44 |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 205 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 194 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 193 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 187 | 31 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 187 | 44 |
| Aripiprazole | Aripiprazole | 183 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 181 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 180 | 40 |
| Levetiracetam | Levetiracetam | 179 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 179 | 15 |
| Simvastatin | Simvastatin | 169 | 40 |
| Ozempic | Semaglutide | 167 | 33 |
| Morphine Sulfate Er | Morphine Sulfate | 165 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 164 | 121 |
| Metformin Hcl Er | Metformin Hcl | 162 | 29 |
| Bumetanide | Bumetanide | 161 | 21 |
| Glimepiride | Glimepiride | 153 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 152 | 65 |
| Vraylar | Cariprazine Hcl | 152 | 13 |
| Glipizide | Glipizide | 151 | 34 |
| Trulicity | Dulaglutide | 146 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 139 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 137 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 135 | 15 |
| Ibuprofen | Ibuprofen | 134 | 23 |
| Farxiga | Dapagliflozin Propanediol | 131 | 27 |
| Olanzapine | Olanzapine | 130 | 23 |
| Azithromycin | Azithromycin | 128 | 111 |
| Januvia | Sitagliptin Phosphate | 128 | 19 |
| Cefdinir | Cefdinir | 127 | 109 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 122 | 24 |
| Topiramate | Topiramate | 119 | 14 |
| Alendronate Sodium | Alendronate Sodium | 118 | 29 |
| Colestipol Hcl | Colestipol Hcl | 118 | 20 |
| Fenofibrate | Fenofibrate | 118 | 21 |
| Glipizide Er | Glipizide | 113 | 32 |
| Ketoconazole | Ketoconazole | 111 | 32 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 111 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 110 | 16 |
| Ezetimibe | Ezetimibe | 105 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 105 | 43 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 19 |
| Valsartan | Valsartan | 103 | 26 |
| Bupropion Xl | Bupropion Hcl | 100 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 97 | 18 |
| Nystatin | Nystatin | 97 | 41 |
| Dicyclomine Hcl | Dicyclomine Hcl | 96 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 93 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 92 | suppressed |
| Temazepam | Temazepam | 91 | 21 |
| Lovastatin | Lovastatin | 90 | 21 |
| Entresto | Sacubitril/Valsartan | 87 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 83 | 14 |
| Azelastine Hcl | Azelastine Hcl | 82 | 37 |
| Sucralfate | Sucralfate | 80 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 74 | 13 |
| Mupirocin | Mupirocin | 73 | 50 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 72 | 16 |
| Linzess | Linaclotide | 72 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 14 |
| Lamotrigine | Lamotrigine | 70 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 70 | 13 |
| Fentanyl | Fentanyl | 69 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 67 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 67 | suppressed |
| Irbesartan | Irbesartan | 66 | 18 |
| Ondansetron Odt | Ondansetron | 66 | 24 |
| Benztropine Mesylate | Benztropine Mesylate | 65 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 52 |
| Bupropion Hcl Sr | Bupropion Hcl | 61 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 59 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 59 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 59 | 11 |
| Propranolol Hcl | Propranolol Hcl | 58 | 11 |
| Primidone | Primidone | 57 | 11 |
| Valacyclovir | Valacyclovir Hcl | 57 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 55 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 55 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 38 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 54 | suppressed |
| Gemtesa | Vibegron | 53 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 53 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | suppressed |
| Latanoprost | Latanoprost | 51 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 51 | 14 |
| Fluconazole | Fluconazole | 50 | 39 |
| Lactulose | Lactulose | 50 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 34 |
| Estradiol | Estradiol | 49 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 49 | suppressed |
| Levofloxacin | Levofloxacin | 49 | 38 |
| Metoclopramide Hcl | Metoclopramide Hcl | 48 | 11 |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Cephalexin | Cephalexin | 46 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 46 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 45 | suppressed |
| Methotrexate | Methotrexate Sodium | 45 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 45 | suppressed |
| Haloperidol | Haloperidol | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 11 |
| Naproxen | Naproxen | 44 | 11 |
| Atenolol | Atenolol | 43 | 14 |
| Clonidine Hcl | Clonidine Hcl | 43 | 15 |
| Doxepin Hcl | Doxepin Hcl | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 40 |
| Movantik | Naloxegol Oxalate | 43 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | suppressed |
| Cilostazol | Cilostazol | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 27 |
| Venlafaxine Hcl | Venlafaxine Hcl | 42 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | 11 |
| Risperidone | Risperidone | 40 | suppressed |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Digoxin | Digoxin | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 37 | suppressed |
| Carisoprodol | Carisoprodol | 36 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Torsemide | Torsemide | 36 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 34 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 19 |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 32 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Loperamide | Loperamide Hcl | 31 | 12 |
| Mometasone Furoate | Mometasone Furoate | 31 | suppressed |
| Bicalutamide | Bicalutamide | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | 11 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | 12 |
| Calcitriol | Calcitriol | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 20 |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Sulfasalazine | Sulfasalazine | 27 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 27 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 26 | suppressed |
| Felodipine Er | Felodipine | 26 | suppressed |
| Multaq | Dronedarone Hcl | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 26 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 25 | 11 |
| Glyburide | Glyburide | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Paliperidone Er | Paliperidone | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Constulose | Lactulose | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Azathioprine | Azathioprine | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Leflunomide | Leflunomide | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | 13 |
| Budesonide Dr | Budesonide | 19 | suppressed |
| Fluorometholone | Fluorometholone | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Novolin R | Insulin Regular, Human | 18 | suppressed |
| Nystop | Nystatin | 18 | 11 |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Veozah | Fezolinetant | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,000.83 · 170 records | ABBVIE INC. | ABRYSVO, AREXVY, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, HETLIOZ, INCEPTIV, INGREZZA, JARDIANCE, Kerendia, LINZESS, MAVYRET, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PENMENVY, PREVNAR 20, PURAPLY WOUND MATRIX, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, Senza, Sunosi, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error